April 15, 2025

Acurion Rebrands and Innovates in Precision Oncology

Community Resource Consultants Inc. (CRCI)

Community Resource Consultants Inc. (CRCI) is a Michigan-based organization specializing in trauma rehabilitation medical case management. With over 34 years of experience, CRCI is dedicated to empowering survivors of catastrophic auto accidents to regain control of their lives and achieve both physical and emotional well-being. Their team of Licensed Master Social Workers (LMSWs) and Registered Nurses (RNs) are experts in navigating the complexities of today’s healthcare system, ensuring that survivors receive the necessary services for their recovery and rehabilitation. CRCI’s core values include advocacy, people, knowledge, and dependability, reflecting their commitment to being leading advocates and facilitators of long-term collaborative care.

News Summary

Acurion, formerly known as io9, announces a transformative rebranding alongside a new leadership team to revolutionize cancer care. Their flagship OncoGaze™ platform promises to accelerate diagnosis and treatment for patients, aiming to cut therapy initiation time dramatically. With plans for a Series A fundraising in 2025, Acurion’s vision is to provide oncologists with crucial genomic insights, making precision therapies more accessible. This new direction signals a commitment to improving patient outcomes in the fight against cancer.

Big Changes for Acurion: A New Name and Ambitious Plans Ahead!

Guess what? Acurion, the innovative healthcare company that previously went by the name io9, has just announced a major rebranding effort. This is not just a pretty new logo; it’s a thoughtful change that reflects the company’s evolving mission and future aspirations in the ever-important field of precision oncology!

Meet the New Leadership Team

With the rebranding comes a fresh leadership team, set to steer Acurion into its next chapter. At the helm is Rick Fultz, the Chief Executive Officer, who has over 15 years of experience guiding growth within the life sciences sector. Alongside him are other seasoned experts like Feng Cao, Ph.D., taking on the role of Chief Operating Officer, and Ludmil Alexandrov, Ph.D., who steps in as Chief Scientific Officer. Erik Bergstrom, Ph.D., serves as the Chief Technology Officer, while Shelly Vandertie manages the finances as the Vice President of Finance.

These leaders are not only experienced but are also passionate about revolutionizing cancer care. Together, they plan on tackling the challenges and barriers that have long puzzled patients and healthcare providers alike.

What’s Acurion’s Game Plan?

One of Acurion’s primary goals is to significantly cut down on the often lengthy delays from diagnosis to the initiation of therapy. Each moment matters when it comes to cancer treatment and Acurion believes they have the tools to make that process swifter and smoother. The company’s flagship innovation is the OncoGaze™ platform, a futuristic artificial intelligence system that was spotlighted on CNN’s Global Innovations. This cutting-edge technology is designed to identify genomic biomarkers from tumor biopsy slides faster than ever before.

Imagine this: the time it usually takes for patients to receive their first-line treatment could drop from weeks to mere seconds! Acurion aims to position OncoGaze™ as a reliable and accessible option for oncologists around the world, thereby making critical precision therapies more widely available.

What Makes OncoGaze™ Special?

Now, you might be wondering, how does OncoGaze™ stand apart from existing solutions? Well, it’s designed to be more accurate than traditional FDA-approved genomic testing methods, adding a new layer of reliability and efficiency to cancer care. In fact, Acurion’s technology has even been recognized in the esteemed Journal of Clinical Oncology, indicating robust support within the oncology community.

Funding the Future

As part of these exciting developments, Acurion has announced plans to kick off its Series A fundraising on April 15, 2025. This is a critical step to fund their ongoing growth and innovation efforts. By collaborating with research institutions, patient advocacy groups, and industry leaders, Acurion aims to amplify its impact in the precision oncology realm.

Through these initiatives, Acurion aspires to transform frontline cancer care by providing oncologists with the key genomic insights they need to expedite effective treatments. No one should navigate the grave landscape of cancer treatment alone, and Acurion is here to change that.

Looking Ahead

With the new branding, enhanced technology, and an inspired leadership team, Acurion appears set to significantly impact the world of oncology. Their mission goes beyond mere innovation; it’s about making a real difference—helping cancer patients get the care they need when they need it most.

It’s an exciting time for Acurion and for the patients who stand to benefit from their groundbreaking work. Keep an eye on this company; it’s clear they’re gearing up for groundbreaking changes in cancer treatment!